Amivantamab-lpuj 160 mg/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro]
RxNorm 2729305

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2729305 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: amivantamab-lpuj 160 mg/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
Amivantamab-lpuj 160 mg/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro]
AUI:13021567
View
SY
Rybrevant Faspro 160 mg / 2000 UNT per mL Injection
AUI:13041039
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBD

Semantic Branded Drug (SBD):
Amivantamab-lpuj 160 mg/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro]
(Atom ID: 13021567)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
E
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2729305
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
13021567
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2729305
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SY

Synonym (SY):
Rybrevant Faspro 160 mg / 2000 UNT per mL Injection
(Atom ID: 13041039)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Rybrevant Faspro 160 MG / 2000 UNT per ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
E
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2729305
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
13041039
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2729305
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.